ExeVir’s unique platform uses heavy chain-only (VHH) antibody fragments derived from camelid single-domain antibodies. The small size and flexibility of the VHH antibody fragments means they can be used like building blocks – linked together into a single drug molecule capable of addressing multiple targets on a bacterial cell or viral particle. These multi-specific antibodies are particularly helpful in tackling fast-moving mutations, giving ExeVir therapies an advantage against disease variants and subtypes.
Thanks to the short throughput time needed to generate new drug candidates, ExeVir’s modular platform can be used to respond rapidly to existing and future threats to public health. The resulting therapeutics are stable, cost-effective, and easy to produce, facilitating global access to protection and treatment.
ExeVir collaborates closely Belgium’s leading life sciences research institute VIB, developing new VHH antibodies together with the laboratories of Prof. Xavier Saelens and Prof. Nico Callewaert (VIB – Ghent University).